Brief: Santhera Pharmaceuticals Announces Positive Topline Results From Its Long-Term Phase 4 Leros Study With Raxone

Santhera Pharmaceuticals Holding AG

23/06/2021 06:01

June 23 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG
 SANN.S :
    * SANTHERA ANNOUNCES PHASE 4 LEROS TRIAL WITH RAXONE® MET
PRIMARY
ENDPOINT IN PATIENTS WITH LEBER'S HEREDITARY OPTIC NEUROPATHY
    * ANNOUNCES POSITIVE TOPLINE RESULTS FROM ITS LONG-TERM
PHASE 4
LEROS STUDY WITH RAXONE® (IDEBENONE) IN TREATMENT OF LEBER'S
HEREDITARY OPTIC NEUROPATHY (LHON)

Source text for Eikon:  ID:nGNE1TrGr9 
Further company coverage:  SANN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))